Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus

Inclusion Criteria: * Subjects must be 18 years and older * Subjects must have a diagnosis of type 1 or type 2 diabetes mellitus * Subjects must be available to participate in all clinical sessions with the following parameters: * Subject must be willing to wear 1 sensor on each upper arm simultaneously. * Subjects must be willing to have their glucose levels manipulated in each in-clinic visit. * Subjects must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol. * Subjects must be willing and able to provide signed written consent. * Subjects must be able to speak, read and write English. Exclusion Criteria: * Known allergy and not able to tolerate to medical grade tape adhesive. * Presence and unresolved of extensive skin changes/diseases at sensor wear site(s) that preclude wearing the sensor(s) on skin * Subjects who have or are female of child-bearing potential age: * Has a positive pregnancy screening test * That plans to become pregnant during the course of study. * Diagnosed with hemophilia or any other bleeding disorders * Acute or chronic kidney disease * Currently managed by dialysis or anticipating initiating dialysis during the course of study. * Current or know history of coronary artery or cardiovascular disease that is not stable with medical management thromboembolic disease. * Any condition that, in the opinion of the Investigator, would interfere with their participation in the study or pose excessive risk to study staff. * Prior to enrollment, subject has had: * Severe hypoglycemia within past 6 months. * History of Diabetic Ketoacidosis (DKA) within the past 6 months, * History of a seizure disorder within the last 6 month * Hypoglycemia unawareness. * Severe diabetes related complications. * Required or scheduled to have a Magnetic Resonance Imagining (MRI) scan, Computed Tomography (CT) scan, or diathermy during the study wear period. * Plans to donate blood during the course of the study * Insulin-dependent type 2 subjects that receive sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor) treatment\[14\] * Hematocrit (Hct) level lower than the normal reference range * Weight less than 110 pounds (50 kg) * Participated in another clinical trial within 2 weeks prior to screening * Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment.